Health Economics›B-cell acute lymphoblastic leukemia pediatric›Delayed intensification 6

Delayed intensification 6

B-cell acute lymphoblastic leukemia pediatric · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
AALL0932 delayed intensification Variant #01 Partial	—	R 9 012	56d	—	—	~1	~R 9 012 indirect	—

1 of 1 regimen shown